Status:
COMPLETED
Translational and Clinical Aspects of Metabolic, Anabolic and Endothelial Dysfunction in Heart Failure
Lead Sponsor:
Lars Lund
Conditions:
Heart Failure With Reduced Ejection Fraction HFrEF
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
In patients with HF cardiac output, metabolism and endothelial function will be studied during and after treatment with ghrelin infusion
Detailed Description
In patients with HF cardiac output, metabolism and endothelial function will be studied during and after treatment with ghrelin infusion (single dose). The following parameters will be collected: rou...
Eligibility Criteria
Inclusion
- Current or past signs of clinical HF according to the Framingham criteria
- LVEF\<40%
- NT-proBNP \> 300 ng/L
Exclusion
- Inability to or unwillingness to provide informed consent,
- Participation in research study that involves research drug administration or contraindication to any of the clinically indicated procedures.
Key Trial Info
Start Date :
February 17 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 22 2014
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT05277415
Start Date
February 17 2013
End Date
May 22 2014
Last Update
October 23 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.